Immix Biopharma Prices $125M Underwritten Offering at $11.00/Share
IMMX has more than doubled off its 52-week low of $1.99.
Summary
Immix Biopharma priced an underwritten offering of 11.36 million shares at $11.00, raising $125 million gross to fund NXC-201 development and working capital. The underwriting agreement was signed on September 29, 2026, with closing expected September 30, 2026.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The underwriting agreement with J.P. Morgan was signed on September 29, 2026, with closing expected September 30, 2026.
Key Events · Financing and Capital Events · IMMX
-
Updated · · SEC 8-K
Underwritten Offering Priced and Underwriting Agreement Signed
11,363,637 shares offered at $11.00 per share for $125,000,007 gross proceeds; J.P. Morgan is sole book-running manager. The underwriting agreement was signed on September 29, 2026, with closing expected September 30, 2026.
-
Dilution Impact
Post-offering share count rises to 83,079,249 from 71,535,679, representing approximately 15.9% dilution to existing holders.
-
Net Proceeds and Use
Net proceeds of approximately $117.1 million after $7.5 million underwriting discount and $0.4 million expenses, earmarked for NXC-201 clinical development and general corporate purposes.
-
Investor Dilution per Share
Pro forma as-adjusted net tangible book value of $4.17 per share results in $6.83 per share immediate dilution to new investors.
Analysis · IMMX · Life Sciences
Immix Biopharma is raising $125 million in a firm commitment underwritten offering, selling 11.36 million shares at $11.00 each — a 4.1% discount to the September 28 closing price of $11.47. The deal adds roughly 15.9% to the share count and dilutes new investors by $6.83 per share against a pro forma net tangible book value of $4.17. The capital extends the company's runway for NXC-201 development, but the pricing below the last close and the size of the raise relative to the company's $820 million market cap make this a meaningful financing event for existing holders. The underwriting agreement with J.P. Morgan was signed on September 29, 2026, with closing expected September 30, 2026.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1498 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMX was trading at $12.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $820.6M. The 52-week trading range was $1.99 to $15.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.